In brief, we confirmed the specificity of commercially available CD44 antibodies by immunoblotting transfected cell samples overexpressing specific CD44 variants. We then applied the validated antibodies to examine the distribution of CD44 variant expression levels in normal and AD brain tissues using immunohistochemistry. The experimental conditions and results of this study are summarized in Table 1.

This work was supported by the Emory Center for Neurodegenerative Disease Neuropathology and Viral Vector Cores, Emory Integrated Genomics Core, and the NIH National Institutes on Aging TREAT-AD Center for Alzheimer's Disease grant U54AG065187.